Micell Technologies Inc:企業の製品パイプライン分析2018

GlobalDataが発行した調査報告書(DATA904C12770)
◆英語タイトル:Micell Technologies Inc - Product Pipeline Analysis, 2018 Update
◆商品コード:DATA904C12770
◆発行会社(リサーチ会社):GlobalData
◆発行日:2018年12月
◆ページ数:33
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:アメリカ
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD1,500 ⇒換算¥222,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD2,250 ⇒換算¥333,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Micell Technologies Inc (Micell) is a medical device company that develops drug delivery systems for the treatment of cardiovascular diseases. The company provides product such as MiStent sirolimus eluting absorbable polymer coronary stent system, a drug-eluting stent that is designed to optimize healing. It offers novel drug-coated balloon to deliver sirolimus to the artery wall at the site of a percutaneous transluminal angioplasty and stent implantation for peripheral and coronary indications. Micell provides a fluid-based technology platform to provide control over drug morphology and apply multiple therapeutic agents in single or multiple layers to achieve tailored therapeutics. The company also conducts clinical and pre-clinical trials. Micell is headquartered in Durham, North Carolina, the US.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Micell Technologies Inc
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons to Buy:

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
Micell Technologies Inc Company Overview 4
Micell Technologies Inc Company Snapshot 4
Micell Technologies Inc Pipeline Products and Ongoing Clinical Trials Overview 4
Micell Technologies Inc – Pipeline Analysis Overview 6
Micell Technologies Inc – Key Facts 6
Micell Technologies Inc – Major Products and Services 7
Micell Technologies Inc Pipeline Products by Development Stage 8
Micell Technologies Inc Ongoing Clinical Trials by Trial Status 10
Micell Technologies Inc Pipeline Products Overview 12
Bioresorbable Scaffold (BRS) 12
Bioresorbable Scaffold (BRS) Product Overview 12
Drug-Coated Balloon 13
Drug-Coated Balloon Product Overview 13
MiStent SES 14
MiStent SES Product Overview 14
MiStent SES Clinical Trial 15
Peripheral Drug-Eluting Stent 17
Peripheral Drug-Eluting Stent Product Overview 17
Micell Technologies Inc – Key Competitors 18
Micell Technologies Inc – Key Employees 19
Micell Technologies Inc – Locations And Subsidiaries 20
Head Office 20
Recent Developments 21
Micell Technologies Inc, Recent Developments 21
May 23, 2018: Positive Two-Year Data from MiStent DESSOLVE III Trial Presented at EuroPCR – Excellent Safety And Low Target Lesion Revascularization (TLR) Rates Persist 21
Mar 20, 2018: Micell Technologies Announces Expanded Patent Estate 22
Jan 09, 2018: Positive Five-Year Data Published for MiStent in EuroIntervention 22
Dec 06, 2017: The Lancet Publishes Twelve-Month Results for DESSOLVE III Highlighting MiStent Performance in All-Comers Randomized Trial; MiStent Achieved Primary Endpoint vs Xience 22
May 16, 2017: Micell Technologies Announces MiStent Achieved Primary Endpoint in All-Comers Randomized Clinical Trial Versus Xience 23
Nov 28, 2016: Micell Technologies Announces First Patient Enrolled In Landmark Registration Trial Of MiStent In Japan 24
Oct 31, 2016: Positive Five-Year Clinical Data from Micell Technologies’ MiStent Presented at TCT 2016 25
Mar 22, 2016: Micell Technologies Completes Enrollment in OCT Study Designed to Evaluate Superior Performance of MiStent SES Compared to Xience 26
Feb 25, 2016: Micell Technologies Highlights Data From Published Propensity Analysis of MiStent SES and Market Standard Xience V Coronary Stent 27
Dec 09, 2015: Micell Technologies Announces Completion of Enrollment in MiStent Randomized Trial against Xience 28
Appendix 30
Methodology 30
About GlobalData 33
Contact Us 33
Disclaimer 33

List of Tables
Micell Technologies Inc Pipeline Products and Ongoing Clinical Trials Overview 4
Micell Technologies Inc Pipeline Products by Equipment Type 5
Micell Technologies Inc Pipeline Products by Indication 5
Micell Technologies Inc Ongoing Clinical Trials by Trial Status 5
Micell Technologies Inc, Key Facts 6
Micell Technologies Inc, Major Products and Services 7
Micell Technologies Inc Number of Pipeline Products by Development Stage 8
Micell Technologies Inc Pipeline Products Summary by Development Stage 9
Micell Technologies Inc Ongoing Clinical Trials by Trial Status 10
Micell Technologies Inc Ongoing Clinical Trials Summary 11
Bioresorbable Scaffold (BRS) - Product Status 12
Bioresorbable Scaffold (BRS) - Product Description 12
Drug-Coated Balloon - Product Status 13
Drug-Coated Balloon - Product Description 13
MiStent SES - Product Status 14
MiStent SES - Product Description 14
MiStent SES - A Prospective, Single-blinded, Multi-center, Randomized, Controlled, Registered Clinical Trial on the Efficacy and Safety of Sirolimus-eluting Stent (MiStent System) in the Treatment of Patients with Coronary Heart Disease 15
MiStent SES - MiStent Sirolimus Eluting Absorbable Polymer Coronary Stent System (MiStent SES) Optical Coherence Tomography (OCT) 15
MiStent SES - Multicenter Randomized Study of the MiStent Sirolimus Eluting Absorbable Polymer Stent System (MiStent SES) for Revascularization of Coronary Arteries 15
MiStent SES - Multicenter Randomized Study of the Mistent Sirolimus Eluting Absorbable Polymer Stent System (MT005) for Revascularization of Coronary Arteries 16
Peripheral Drug-Eluting Stent - Product Status 17
Peripheral Drug-Eluting Stent - Product Description 17
Micell Technologies Inc, Key Employees 19
Glossary 32

List of Figures
Micell Technologies Inc Pipeline Products by Equipment Type 5
Micell Technologies Inc Pipeline Products by Development Stage 8
Micell Technologies Inc Ongoing Clinical Trials by Trial Status 10

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Micell Technologies Inc:企業の製品パイプライン分析2018(Micell Technologies Inc - Product Pipeline Analysis, 2018 Update)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆